Sterling Pharma Solutions Secures $10 Million in Funding to Drive Innovation and Expand Global Reach

Sterling Pharma Solutions, a leading global contract development and manufacturing organization (CDMO), has successfully raised $10 million to enhance its operations and service delivery in the pharmaceutical industry. With over 50 years of experience, Sterling has established itself as a pioneer in providing specialized small molecule API development and manufacturing services, managing some of the most challenging chemistries in the sector. This latest funding underscores Sterling's commitment to expanding its capabilities, particularly in the areas of Antibody Drug Conjugate (ADC) development and manufacturing. With six state-of-the-art facilities located across the UK, USA, and Europe, and a dedicated workforce of over 1,350 professionals, Sterling is poised to leverage this financial boost to innovate and streamline its processes, enhance production capacity, and further solidify its position as a trusted partner in drug development. Sterling's ethos of simplifying complex science into robust partnerships is vital in an industry where collaboration and transparency are essential. The infusion of $10 million will not only support the company’s infrastructure but will also foster deeper relationships with clients, ensuring that they receive high-quality service from proof-of-concept to commercial manufacture. As a testament to its dedication to redefining the CDMO experience, Sterling remains firmly committed to exemplifying the principles of trust and transparency, thus paving the way for new advancements in pharmaceutical development. For more insights into their operations, visit www.sterlingpharmasolutions.com/sterling-facilities.